Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer Sep 11, 2017
Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Sep 05, 2017
Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Sep 05, 2017
Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer) Aug 15, 2017
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases Aug 14, 2017
Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights Aug 14, 2017
Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights Aug 11, 2017
Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights Aug 09, 2017
